August 16, 2024, 6:00 AM EDT | Source: Therma Bright Inc.
Toronto, Ontario–(Newsfile Corp. – August 16, 2024) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), a broad-based development and investment partner for cutting-edge proprietary diagnostic and medical device technologies, is pleased to announce that its AI-powered Digital Cough Technology (DCT), developed in collaboration with development partner AI4LYF, is currently being considered as a partner technology for a U.S.-based clinical trial of a new innovative and disruptive chronic cough medication.
“We are pleased to hear from our development partners in AI4LFY that our AI-powered DCT platform is the leading candidate for use in a U.S. clinical trial with a major pharma brand's new innovative chronic cough medication,” said Rob Fear, CEO of Therma Bright. “Our DCT solution and data collection platform are perfectly positioned for clinical trials such as this one, enabling healthcare professionals and epidemiologists to make more accurate and informed clinical decisions to rapidly address respiratory issues for a patient or group of patients.”
Additionally, as reported in November 2023, the Company continues to work on the U.S. Food and Drug Administration's (FDA) 513(g) request to obtain information regarding the classification and regulatory requirements for its Acoustic AI Digital Cough Technology as a remote therapy monitoring (RTM) solution. To further this work, additional materials are being prepared, including patient and healthcare user guides, a mobile cough collection app for DCT, and a desktop/mobile app data capture and reporting platform.
Additionally, as the Venowave VW5 solution awaits final approval of its permanent reimbursement code from the U.S. Centers for Medicare and Medicaid (CMS), the Company is investigating the possibility that its AI-powered DCT platform may secure a permanent CMS reimbursement code designation and become eligible for other federal funding and grant support.
The Company, together with its partners in AI4LYF, will continue to consult with key strategic partners and advisory networks while updating the market on all the above initiatives and opportunities.
Therma Bright's AI-powered DCT platform, in collaboration with partner AI4LYF, is focused on supporting medical decision-making by improving the collection, organization and presentation of cough and breathing data to healthcare providers and epidemiologists, the public health workers who study breathing patterns.
About Therma Bright Inc.
Therma Bright develops and partners a broad range of cutting-edge, proprietary diagnostic and medical device technologies, focused on providing consumers and medical professionals with high-quality, innovative solutions that address some of today's most significant medical and healthcare challenges. Therma Bright Inc. trades (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit www.thermabright.com.
About AI4LYF
AI4LYF is an innovative smart health company with a mission to transform people's lives through deep intelligence. As a pioneer in DCT, we are also working on new AI-based solutions that have the potential to transform “reactive disease treatment” into “predictive, preventive and personalized healthcare” to help everyone live a fuller and longer life.
Forward-Looking Statements
This news release contains “forward-looking” statements. These statements relate to future events, such as the commercialization of DCT and related technologies described in this news release. All such statements involve substantial known and unknown risks, uncertainties and other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements. Forward-looking statements involve significant risks and uncertainties and are not guarantees of future performance or results, nor will they necessarily be accurate indications of whether such results will be achieved. Actual results may differ materially from expectations as a result of a number of factors and risks. Although the forward-looking statements contained in this news release are based on reasonable assumptions of the Company's management as of the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220173
Source: Therma Bright Inc.
